Status:
UNKNOWN
Assess the Correlation With Severe Respiratory Syncytial Virus Disease in the First 6 Months in Children With Congenital Heart Disease and Maternal Ac-AntiVSR Titers During Pregnancy
Lead Sponsor:
Hospital Angeles Lomas
Conditions:
Respiratory Syncytial Virus, Congenital Heart Disease
Eligibility:
All Genders
1-12 years
Brief Summary
Passive transplacental immunity against the respiratory syncytial virus (RSV) appears to mediate infant protection during the first 6 months of life (1). Observations of environmental exposure in preg...
Detailed Description
A prospective cohort study of mothers with a prenatal diagnosis of a fetus with congenital heart disease will be carried out. To whom titers will be measured. Anti-RSV IGG antibodies result from previ...
Eligibility Criteria
Inclusion
- Pregnant mothers in the third trimester of gestational age, with a child with congenital heart disease diagnosed by fetal echocardiogram
- Approval of informed consent
- Newborn of term or preterm, with corroborated congenital heart disease and presenting with a respiratory infection by RSV
Exclusion
- \- Non-acceptance of informed consent
- \- Premature birth and need for neonatal intensive care for more than 4 weeks.
- \- Newborn with bronchopulmonary dysplasia
- Elimination criteria
- - Use of palivizumab
Key Trial Info
Start Date :
February 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04734782
Start Date
February 15 2021
End Date
March 31 2022
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Medico Nacional 20 de Noviembre
Mexico City, Mexico, 03100